EGFR and cancer: Inhibitors of oncogene products, such as the epidermal growth factor receptor (EGFR), the anaplastic lymphoma kinase (ALK), the ABL tyrosine kinase, BRAF, and JAK2 kinases, are able to inhibit glycolysis; consequently, drug-resistant oncogene-addicted cancer cells exhibit higher aerobic mitochondrial respiration, display higher stemness, and are metabolically reprogrammed to depend on OXPHOS for survival.